NHL, representing significant cost savings in several studies.
PBPC involves no anesthesia risk compared with ABMT Intensive high-dose chemotherapy with autologous stem-cell support has become a common treatment which requires hospitalization and anesthesia. In recent years, PBPC has become the standard care in France strategy for non-Hodgkin's lymphomas. A cost-identification analysis was conducted comparing 10 patients over ABMT. The French National Health Insurance is concerned, as autografted with PBSC to 10 others autografted with BM. The analysis included harvest and graft until graft in many countries, by the increasing high costs of health care. Hematological departments are commonly the most day +100 and was carried out from the point of view of the hospital setting. Resources used, logistic and direct expensive wards in French university medical school hospitals. Studies comparing cost treatment in patients with NHL medical costs per patient were identified, and sensitivity analyses performed. The cost distribution was different.
have been published from different health care systems, [3] [4] [5] including one in France by a private Cancer Center. 6 The Stem cell harvest was more expensive for PBPC ($9030) and BM ($4745); on the other hand, hospitalization aim of this study was to carry out a cost-identification analysis comparing PBPC and BM autologous transfrom graft to discharge from hospital cost savings with PBSC were about $10 666. After discharge from hospiplantations in NHL for patients treated with successive protocols. tal, costs were similar and cheaper in both groups. For the overall study the PBPC procedure was less expens-A retrospective economic analysis was carried out in the Besançon university medical school hospital. Ten patients ive than ABMT, $35 381 and $41 759 respectively, with cost savings of $6378. The number of days spent in hosautografted with BM were compared with 10 others autografted with HGF primed PBPC. The economic assessment pital and blood bank costs were the major cost factors. This study was based on a single pathology, non-Hodgwas based on a cost analysis using the hospital perspective. kin's lymphoma, and the actual hospital records for each patient situation as opposed to a clinical trial, and our results were consistent with different previous studMaterials and methods ies carried out in different health care systems. Keywords: lymphomas; cost analysis; ABMT; PBSC; Patients hematopoietic growth factor Consecutive patients treated in the university of FrancheComté medical school hematology unit with HDC for NHL between 1992 and 1994 were identified. Every patient who Intensive high-dose chemotherapy (HDC) with autologous underwent high-dose chemotherapy and autologous bone peripheral blood progenitor cells (PBPC) and bone marrow marrow or peripheral stem cell transplantation was (BM) support is a common treatment strategy for interincluded. Analysis was performed for patients for whom mediate-or high-grade non-Hodgkin's lymphoma (NHL) data were available until graft day +100 post-graft. in first remission or after relapse.
1,2 Hematopietic growth All patients included were treated in first line, except one factors (HGF) such as G-CSF or GM-CSF facilitate PBPC patient with a delayed relapse. Ten patients were automobilization and accelerate engraftment after transplangrafted with unpurged marrow between 1992 and the end tation. To date, PBPC transplant has been shown to be as of 1993. Subsequently, 10 patients received PBSC transsafe and effective as ABMT for Hodgkin disease (HD) and plantation between the end of 1993 and July 1994. Patient characteristics are summarized in Table 1 . according to the GOELAM 07 protocol. 7 Fifteen were modified according to standard practice for neutropenia. Patients were treated in single rooms and received oral intensified in complete response (BMT, eight; PBPCT, seven) and five in partial remission (PR). The mean period decontamination with non-absorbable antibiotics (gentamicin) and amphothericin B. No growth factor was systembetween diagnosis and graft was around 6 months, except for one patient who relapsed after 5 years and had a subatically prescribed post-transplantation. Patients were discharged when the absolute neutrophil count reached sequent second complete response.
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PBPC collections were consecutive after mobilization by Ͼ0.5 × 10 9 /l, if they were without fever or infections. After discharge from hospital, patients were either rehospitalized chemotherapy and HGF (8 filgrastim, 2 molgrastim). In the PBPC group, HGF was initiated at the end of mobilization (one patient) or followed in outpatients, on the day ward or both. chemotherapy and maintained daily until the end of cytapheresis procedures. Four patients had two leukapheresis procedures performed, three patients needed three and one Economic assessment patient four procedures. Two patients failed at the first procedure and needed another different cycle of HGF stimuData collection concerned the harvest period and the period from HDC until discharge from hospital, and finally the lation for priming PBPC. Bone marrow harvests were consecutive after cycles of chemotherapy, according to the post-graft period until graft day +100. Since January 1983, French public hospitals have been managed on the basis of LNH 87 (n = 6) and the GOELAM 07 protocol (n = 4) ( Table 1) . a global budget allocated by the National Health Insurance every year. However, an analytic accounting system still has to be developed. Therefore, costing units of health care Supportive care utilization in the hospital setting in France relies on a mix of the per diem method and standard cost for specific During transplant and post-transplant periods, all patients were hospitalized in an intensive care hematological unit.
services and procedures. Resources used and direct medical costs were identified Platelet transfusion units were given when the platelet count was less than 20 × 10 9 /l or in cases of bleeding with for each patient. All treatment consequences during study periods were accounted for. The components of care that a low platelet count. Packed red blood cells were transfused to maintain the hemoglobin level over 8 g/dl. All blood were not affected by the autograft within 1 day of hospitalization (eg hotel and basic care) and those that were components were leukocyte-reduced and irradiated and red blood cells were phenotyped. Broad-spectrum i.v. antilikely to be affected by interventions such as drugs and transfusion were identified. The complete hospital structure biotics were given in cases of temperature у38°C and cost (eg overheads, financial expenses), fixed medical or supportive drugs were recorded. All costs were obtained using the unit price multiplied by the total number of logistic costs and variable logistic cost (eg food, laundry) were part of the analytic account. Medical costs were identunits. Unit prices were obtained from wholesale price lists applied to the Besançon Hospital Pharmacy. ified from clinical records observed and computer systems and included laboratory tests, transfusions and drugs. This
• The official tariff for Blood products as published in the 'Journal Officiel' on 22 December 1993 and applied duranalysis was performed from the point of view of the Hospital Institution. Monetary values for 1994 French prices ing 1994 was used (cost per unit multiplied by total number of units). were used for all components. The exchange rate used was 1 US$ = 5 French francs (FRF).
• Bacteriological, virology, biochemistry, hematology and immunology tests were evaluated according to the relevant charge index 'Nomenclature des Actes de Biologie Medical costs (medical resource utilization and costs)
Médicale' (NABM). (Table 2) The following broad categories of service were considered Analysis when assessing resources used:
Differences in mean values of clinical results (number of • The room and overhead analytic accounting system of days of hospitalization, number of days to reach 0.5 × 10 9 /l the 'Assistance Publique-Hôpitaux de Paris' (AP-HP), neutrophils, 1 × 10 9 /l white blood count (WBC), 20 × 10 9 /l which was the only one available in France, obtained and 50 × 10 9 /l platelets, number of days of i.v. antibiotics, from 50 hospitals, was used. 9 These changes included and number of units transfused) were tested using the nonnon-medical and medical costs such as medical and nonparametric Mann-Whitney test. medical personnel, overheads, hotel, small equipment Data were expressed in each group as a mean ± standard (the costs of devices is included in small equipment in deviation (s.d.). The mean rather than the median was used the analytic accounting system), laundry, food, devices as the mean represents the most adequate measurement to except the following medical costs which were obtained represent the cost of patients whose consumption is high from clinical record data (drugs, blood products, labora-(care) and where there is a level of heterogeneity. tory tests). This avoids double accountancy.
Costs are reported as average per patient ± s.d. No stat-• The cost of leukapheresis for PBPC collection and BM istical testing was performed on costs, but extensive sensiharvest was obtained from the Blood Bank tariff and tivity analyses were conducted by varying the clinical and included harvest, processing and cell conservation, then cost parameters in order to test their effect on overall results thawing the cells to graft.
of the study. Four types of sensitivity analyses were con-• Drugs-chemotherapy (used for conditioning regimens), ducted: (1) varying HGF stimulation mean days and unit anti-infectious agents (to prevent infections and treat cost of ABM harvest; (2) varying mean PBSC leukapherfebrile patients with empiric broad-spectrum antibiotics), esis; (3) varying post-graft hospitalization; and (4) varying parenteral nutrition, HGF (used to mobilize PBPC) and post-graft platelet units transfused. This sensitivity analysis was performed to test the robustness of the economic findings. 15.8 days, range 9-33 vs mean 23.5 days, range 11-48, P = Medical consultations and number of laboratory tests were similar in the two groups. 0.031). In the same way, the length of time that intravenous antibiotics were required differed between the two groups After discharge from hospital two patients needed transfusion support; one in each group was transfused as an out-(14.1 days vs 18.7 days, NS) but was not statistically significant.
patient. One patient in the BMT group was readmitted within 100 days post-graft and stayed in hospital for 4 days. The mean number of days to recover and maintain a platelet count у20 × 10 9 /l was significantly shorter in the PBPC group (mean 14.1 days, range 5-60) in comparison Economic assessment with the BMT group (mean 20.9 days, range 12-70, P = 0.01), which reflected significantly fewer platelet transTotal costs are presented in Table 5 . For the overall study, the PBPC procedure was less expensive than autologous fusions (6.1 vs 18.7 units, P = 0.012). The mean number of red blood cell transfusions (6.6 vs 8.8 units, NS) was bone marrow transplantation, with a cost savings per patient of $6378, but the cost distribution was different. similar in the two groups (Table 4) . For delayed hematological recovery one patient needed HGF post-graft for 12 days Stem cell harvest was more expensive for PBPC ($9030) than BM ($4745). The cost increased in PBSC collection in the PBPC group, in comparison with four patients in the BMT group using HGF for a mean of 19 days (Table 4) .
($3020 = 33% of total harvest costs) as compared with BM harvest ($2640 = 56% of total stem cell harvest costs). HosThe cost savings were $6378 representing 15% of total costs. The savings exceeded the costs of HGF priming and pitalization costs were similar (PBPC = $1478 vs BM = $1626), but represented only 16% of the total cost for PBPC collection. PBSC whereas it was 34% for ABMT. PBPC costs were higher due to HGF priming (+$2115 corresponding to 23% of total cost of stem cell harvest) and three leukaphereses Sensitivity analysis (+$2417). None the less, both harvest manipulation and leukaphereses represented 60% for the PBSC group ($5437)
Stem cell harvest cost: For the mean number of days of which can be compared with 56% for harvest bone marrow stimulation by HGF there were savings that were only offmanipulation ($2640) (Table 5) . Globally, harvest costs set in two cases, either when the cost of a BM graft was were approximately 12% of the total cost in ABMT and negative or if the mean number of days of stimulation was 26% in PBPC groups.
multiplied by four (13 × 4 = 52).
The bulk of cost was for hospitalization from graft to
For the mean number of leukaphereses there were savdischarge from hospital. Cost savings for this defined perings that were only made on patients in the PBPC group iod with PBPC transplantation were about $10 666. The which were offset if the cost of the BM harvest was negamost significant savings were achieved with transfusion tive or if the mean number of cytaphereses was multiplied which decreased in PBPC transplant by $4441; transfusion by two (3 × 2 = 6). components were twice as expensive with ABMT where transfusion represented 23% of the graft period cost, whereas it was only 15% in the PBPC group. Moreover, Graft: The length of hospitalization could vary in both directions. Varying the range of hospitalization from −50 the decrease in the length of hospitalization with PBPC transplant explained the savings of $3549, either 62% in to +50% did not alter the savings. For the mean duration of hospitalization there were savings which could only be the PBPC ($15 844) or 53% in the ABMT group ($19 393). The reduced use of drugs saved $1964, essentially due to offset if the PBPC group had to be hospitalized for 5 days longer than the BM group. intravenous antibiotic use which was for a shorter time in the PBPC group than in the ABMT group. Severe sepsis To modify the direction of the savings, either the average number of platelet transfusion units had to be multiplied occurring during neutropenia or slow engraftment led to the use of HGF for four patients in the ABMT group vs one by 3.8 in the PBPC group (22.9 instead of 6.1 units) or decreased by 90% in the ABMT group (1.9 instead of 18.7 in the PBPC group. Hospital costs represented 72% of overall costs in the PBPC group and 87% in the ABMT group. units). For the mean number of platelet transfusion units there were savings which could only be offset if the mean After discharge from hospital, costs were similar in both groups; either 2.5% of overall costs for ABMT or 2.4% number of platelet transfusion units in the BM group was negative. for PBPC.
Average total costs were $35 381 and $41 759 for This sensitivity analysis showed the robustness of our results. patients receiving PBPC infusion or BMT, respectively.
Discussion
by patients undergoing PBPC were significantly less severe than with bone marrow collection. 16 Retrospective studies indicated that the main advantage of substituting BMT with PBPCs was a faster recovery of Numerous published studies have already demonstrated the feasibility of PBPC autotransplantation. 10, 11 In the Sheridan platelet counts, with a concomitant decrease in transfusion requirement. 6, [13] [14] [15] [16] [17] In our study, the number of days spent in study, 12 all patients received both PBPC and bone marrow. Faucher et al 6 and Uyl-de Groot et al 13 found the mean day hospital and blood bank costs were the major cost factors. As expected, the cost analysis showed savings for the to reach 0.5 × 10 9 /l ANC was 10 and 8 respectively, but these patients received autografts for solid tumours or PBPC group. Since PBPC patients experienced a trend toward less neutropenia and, hence, had a trend toward malignant lymphomas and HGF post-graft. Other studies have analyzed the cost of HGF adjunction to autologous fewer hospitalization days, the related cost was $35 381 with savings of $6378 compared with the ABMT group. BMT or PBPC. 6, 13, 14 Our study analyzed non-Hodgkin's lymphoma in the first
The cost savings would be expected to be higher if the PBPC patients had had only two leukapheresis procedures. group of patients treated in our ward with high-dose chemotherapy and PBSC infusion and was directly based on data
The number of leukaphereses influenced stem cell harvest cost. In this study, the mean number of leukaphereses was from clinical records and not from clinical trials.
Although this analysis is based on a small number of three, but with greater expertise this number had decreased to two. The consequence was a reduction in the length of patients, it has the advantage of using a non-selected population. It thus reflects daily medical practice and avoids the hospitalization for harvest and influenced the high cost identified with the PBPC procedure. For three leukapherdiscrepancies between economic outcomes in a clinical trial and routine practice despite the fact that discrepancies are eses the marginal cost was $4285 vs $1527 for two leukaphereses, reducing the total harvest cost from $9030 to $6272. relatively small in hematology, a speciality where standard care is based on protocol. Sensitivity analysis allowed us Thus, the total cost savings increased from $6378 to $9137. Factors associated with decreasing cost were hospital staff, to be relatively confident about the validity of our conclusions, even if cautious because of the small number of blood bank, and technology and processing improvements. 18 patients in each arm. Moreover, the population in this study had a homogeneous pathology requiring high-dose chemoChemotherapy could be given as day care hospitalization for peripheral stem cell harvests and would decrease cost. therapy and autograft. This study did not compare the use of HGF post-graft, which were not given systematically, Costs of conditioning regimens were lower in the ABMT group because of the use of the CBV protocol for four and differed from previous studies. 4, 6 Neutropenia, length of hospitalization and platelet units patients: the BEAM protocol was twice as expensive as the CBV protocol ($701 vs $1120) ( Table 2 ). used decreased during the post-graft period confirming previous studies carried out in different health care sysSensitivity analysis showed that in the range observed in this study, the direction of results supporting PBSC grafting tems.
3,6,13 Our results are consistent with these studies on homogeneous groups of patients with a single pathology, did not vary. Extreme or highly improbable values would be needed to change the direction of the results. high-grade non-Hodgkin lymphoma. Smith et al 3 found that with a PBPC group, 11 days were needed to reach ANC In the same way, using the published data by Smith et al, 3 Faucher et al 6 and Uyl-de Groot et al 13 for duration of Ͼ0.5 × 10 9 /l, whereas 14 days were required for a BMT group in NHL and HD; days of platelet recovery hospitalization, the analysis was always in favor of PBPC with savings of $6159, $5000 and $10 664, respectively (Ͼ20 × 10 9 /l) were 16 and 23 respectively. Faucher et al 6 found that 16 days were needed to recover ANC (Table 6 ). In a relapsed LNH trial, Bennett et al 15 showed that using Ͼ0.5 × 10 9 /l for BM followed by G-CSF and that only 10 days were required for G-CSF primed PBPC. Similarly, 24 post-graft GM-CSF with BMT led to savings of approximately $6630. Forty percent cost savings were obtained days were needed to recover platelets over 20 × 10 9 /l for BMT followed by G-CSF and only 16 days were required from shorter hospitalization (3.5 days less). Two retrospective studies found that PBPC infusion as for G-CSF primed PBPC. Uyl-de Groot et al 13 compared three different groups, PBPC or BMT followed by G-CSF an alternative to BMT resulted in savings of 20% in total direct costs. 6, 11 Our study showed approximately 15%. or BMT alone and found that the number of days required to reach ANC Ͼ0.5 × 10 9 /l were respectively 8, 12.5 and However, in these studies, HGF was systematically used as an adjunct to BMT or PBPCT. 15.
Duration of hospitalization was 15 days in the PBPC plus An European study based on US estimates of costs compared PBPC and BM transplants for lymphomas (non-G-CSF group and 20 days in the BMT plus G-CSF group in Faucher's study. 6 In the study by Smith et al 3 the respective Hodgkin's lymphoma and Hodgkin disease) in 71 patients, with BEAM as a conditioning regimen. 3 The reported estidurations were 17 and 23 days. The Dutch study had durations of 22 and 36 days, respectively. 13 mated costs for PBPC collection or bone marrow harvest of $9500 and $4630 included G-CSF priming. This result No difference in terms of disease-free survival with either procedure was observed in the literature. 15 was similar to $9030 and $4755 found in our study despite the differences in health care between different health sysOutpatient PBPC harvest may further improve the cost effectiveness of PBPC autologous graft and quality of life.
tems. None the less, the significant cost savings were $13 600 due to shorter hospitalization with less supportive Quality of life was better with the PBPC procedure as shown by Le Coroller et al. 16 Anxiety and pain experienced care. 3 However, the estimated costs of ABMT vary greatly
The results of our unicenter study are confirmed by data evaluation of all new protocols as their introduction does 8 Souêtre E, Quing W. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for nonnot systematically incur increasing costs.
